Ardipusilloside I, extracted from ARDISIA PUSILLA A.DC, effectively inhibits the progression of several cancers in animal models and is a potential anti-cancer drug candidate. However, the metabolism and pharmacokinetic characteristics of ardipusilloside I remain unknown. In this study, we developed a highly sensitive liquid chromatography-tandem MS method to determine the ardipusilloside I concentration in rat plasma using ginsenoside Re (whose structure is similar to ardipusilloside I) as the internal standard. After oral administration of ardipusilloside I, its four possible metabolites (M1, M2, M3, and M4, whose structures were determined by MS) were detected in the content from rat small intestine. In rat plasma, however, only M3 and M4 were detected after oral administration of ardipusilloside I. None of the metabolites were detected in plasma samples after intravenous administration of ardipusilloside I to rats. These results indicated that the metabolites, but not the drug itself, were absorbed into plasma after oral administration of ardipusilloside I to rats and that M3 and M4 may be responsible for the antitumor activity of orally administered ardipusilloside I in rat models of cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0031-1298238 | DOI Listing |
Life Sci
August 2014
Department of Pharmacy, School of Stomatology, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China. Electronic address:
Aims: Ardipusilloside I (ADS-I), a triterpenoid saponin isolated from Ardisia pusilla A.DC (Myrsinaceae), has been recently tested for cancer treatment including brain cancer. However, the mechanism of its action remains elusive.
View Article and Find Full Text PDFPlanta Med
April 2012
Department of Pharmacy, School of Stomatology, Fourth Military Medical University, Xi'an, China.
Ardipusilloside I, extracted from ARDISIA PUSILLA A.DC, effectively inhibits the progression of several cancers in animal models and is a potential anti-cancer drug candidate. However, the metabolism and pharmacokinetic characteristics of ardipusilloside I remain unknown.
View Article and Find Full Text PDFZhong Yao Cai
July 2005
Faculty of Pharmacology of Medical College & Key Laboratory of Ministry of Education of Environment and Genes Related to Disease, Xi' an Jiaotong University, Xi' an 710061.
Objective: To study the antitumor effect of ardipusilloside-I (ADS-I) on Lewis pulmonary carcinoma and hepatocarcinoma SMMC-7721.
Methods: Lewis pulmonary metastasizing model was made by Sc. diluted 3-time 20 microl cancer cells in the right sole of C57BL/6 mice, after we treated the mice 14 days with ADS-I orally, cut the neoplasia-foot and weighed, we calculated the inhibitory rate in situ, then put the mice to death after being administrated 11 days continuously, counted the lung medtastasis colony and calculated the metastasis inhibitory rate; Human being hepatocarcinoma model was made by sc.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!